• Intranasal Dexmedetomidine for Pain Relief During Retinopathy of Prematurity Screening in Preterm Infants <30 Weeks Gestation Using Standard Drug Combination

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    Norway
  • Feasibility and Safety of PEX010 Psilocybin Capsules (5 mg and 25 mg) in Military Veterans with Posttraumatic Stress Disorder

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    The Netherlands
  • Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    The Netherlands
  • Effect of dapagliflozin and semaglutide on heart insulin resistance in type 2 diabetes patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Spain
  • Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

    Not yet recruiting

    3 1 1 1
    Belgium France Germany Italy Spain
  • Safety and efficacy of stopping versus maintenance dose of filgotinib, tofacitinib and upadacitinib in adult ulcerative colitis patients in deep remission

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    France
  • Efficacy of intravenous prasinezumab versus placebo in Parkinson’s disease patients with severe GBA mutation: a 104‑week randomized double‑blind study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    France Germany Italy Luxembourg Spain Sweden
  • Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Germany Italy Spain
  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    Austria Belgium Denmark Finland France Germany +8
  • Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

    Not yet recruiting

    4 1 1
    Investigated Drugs:
    Austria Germany

powered by